Why the study?
Are specific genetic variants associated with the development of cancer therapy-related cardiac dysfunction in oncology patients?
Population
852 oncology patients receiving cancer therapy in the discovery cohort, and 1,191 oncology patients in the…
Comparison
Genome-wide association study for genetic… vs Oncology patients without cancer therapy-related…
Design
Meta-analysis
Key result
The intergenic variant rs7652759 near the TP63 gene was identified as a novel susceptibility locus for cancer therapy-related cardiac dysfunction (P=5.64 × 10–6 in discovery, P=0.01 in replication).
Authors
Loading...
Suggests TP63 locus may inform CTRCD susceptibility; leaves open validation for risk stratification before clinical use.
Meta-Analysis (n=2,043)
Are specific genetic variants associated with the development of cancer therapy-related cardiac dysfunction in oncology patients?
p-value: p=5.64 × 10–6
The intergenic region near TP63 (rs7652759) is identified as a novel susceptibility locus for cancer therapy-related cardiac dysfunction, which could inform future genetic risk scores in cardio-oncology.
Martínez-Campelo et al. (2024) conducted a meta-analysis in Cancer therapy-related cardiac dysfunction (CTRCD) (n=2,043). rs7652759 variant at 3q28 locus vs. Controls without CTRCD was evaluated on Cancer therapy-related cardiac dysfunction (CTRCD) (p=5.64 × 10–6). The intergenic variant rs7652759 near the TP63 gene was identified as a novel susceptibility locus for cancer therapy-related cardiac dysfunction (P=5.64 × 10–6 in discovery, P=0.01 in replication).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: